Showing 2771-2780 of 20410 results for "".
Integration of Photobiomodulation Therapy into the Age-Related Macular Degeneration Treatment Landscape
https://reachmd.com/programs/cme/Integration-of-Photobiomodulation-Therapy-into-the-Age-Related-Macular-Degeneration-Treatment-Landscape/35951/Learn about multiwavelength PBM for the treatment of dry AMD, including the MOA, administration, effHow, When, and Why to Conduct Brief AUD Interventions
https://reachmd.com/programs/cme/how-when-and-why-to-conduct-brief-aud-interventions/15213/The burden of AUD is often drowned out by the growing opioid epidemic, but AUD impacts many of our patients. Tune in to find out how you can help.A Memorable Patient Case: Psoriasis & IBD
https://reachmd.com/programs/frontlines-psoriasis/a-memorable-patient-case-psoriasis-and-ibd/10500/Since psoriasis is such a complex disease, it’s not uncommon to encounter challenging patient cases like this one in practice.Imbalance of Bacteria: How the Gut Microbiome Can Impact Systemic Sclerosis
https://reachmd.com/programs/clinicians-roundtable/imbalance-of-bacteria-how-the-gut-microbiome-can-impact-systemic-sclerosis/10380/The incurable disease scleroderma is often undetected or misdiagnosed. But could new insights into the role of the microbiome be a turning point?The A,B,C's of Identifying Melanoma
https://reachmd.com/programs/everyday-family-medicine/the-abcs-identifying-melanoma/9635/Dr. Jennifer Caudle discusses what you need to look out for when it comes to identifying melanoma.Escalate With Intention: Stepwise, Target-Anchored Moves
https://reachmd.com/programs/cme/escalate-with-intention-stepwise-target-anchored-moves/54773/Explore treat-to-target strategies and FcRn inhibitor use to guide outcomes-driven management of generalized myasthenia gravis.Evidence at a Glance: The Totality of Evidence Impacting Clinical Decision-Making in Patients with HFrEF Without a Recent Worsening Event
https://reachmd.com/programs/cme/evidence-at-a-glance-the-totality-of-evidence-impacting-clinical-decision-making-in-patients-with-hfref-without-a-recent-worsening-event/54634/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
https://reachmd.com/programs/cme/emerging-evidence-in-focus-interpreting-data-on-next-generation-csf1r-tkis/48908/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.Beyond Biology: Environmental and Lifestyle Influences in IBD
https://reachmd.com/programs/cme/beyond-biology-environmental-and-lifestyle-influences-in-ibd/56891/Examine the biological mechanisms underlying IBD, including genetic, microbial, environmental, and immune pathways that inform therapeutic targets.Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
https://reachmd.com/programs/cme/applying-the-evidence-tgct-treatment-insights-for-sports-medicine-physicians/48909/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.